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Podoconiosis is a non-infectious tropical lymphoedema causing swelling of the lower legs. Podoconiosis is asso-
ciated with stigma, depression and reduced productivity, resulting in significant socio-economic impacts for
affected individuals, families and communities. It is caused by barefoot exposure to soils and affects disadvan-
taged populations. Evidence from the past 5 y suggests that podoconiosis is amenable to public health interven-
tions, e.g. footwear and hygiene-based morbidity management, which reduce acute clinical episodes. Although
muchhas been learned in recent years, advances in care for these patients andworldwide control requires further
reliable and relevant research. To develop a comprehensive global control strategy, the following key research
priorities are important: better understanding of the global burden of podoconiosis through extended world-
wide mapping, development of new point-of-care diagnostic methods and approaches to define the presence
of the environmental characteristics that contribute to the development of the condition, improving treatment
through an increased understanding of the pathogenesis of dermal changes over time, improved understand-
ing of optimal ways of providing patient care at the national level, including research to optimize behavioural
change strategies, determine the optimum package of care and integrate approaches to deliver robust surveil-
lance, monitoring and evaluation of control programmes.
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Introduction
Podoconiosis is a disabling form of lymphoedema that, through
recurrent painful episodes of acute dermatolymphangioadenitis
and physical deformity, reduces productive working days among
subsistence farmers by 45% each year,1,2 causing progressive
lymphoedema of the lower limb. Affected people are highly stig-
matized,3,4 experience depression5 and face barriers to edu-
cation, employment and a range of social interactions, includ-
ing marriage.3 In 2011 the World Health Organization identified
podoconiosis as one of the neglected tropical diseases (NTDs).6
The disease,which affects genetically susceptible individualswho
go barefoot, is linked to long-term exposure to red clay soil.7
Interactions between genetic and environmental factors trigger
an inflammatory response that leads to lymphoedema and fibro-
sis.8 Here we review recent progress in understanding this impor-
tant clinical condition and identify the operational research ques-
tions (Box 1) that will support the further development of global
control and elimination strategies.
Box 1. Key research questions
Basic sciences
 Which mineral particles in the soil are responsible for causing
podoconiosis?
 What immunological changes occur as a result of podoconiosis?
 What pathological changes occur in the human lymphatic sys-
tem due to podoconiosis?
Diagnosis
 What is the accuracy and reproducibility of diagnosis of podoco-
niosis using a clinical algorithm in different epidemiological set-
tings?
 Can spectroscopy combined with machine learning be used for
the diagnosis of podoconiosis or to predict the risk of podoconio-
sis in the preclinical stage?
 What molecular test might be used to diagnose podoconiosis?
© The Author(s) 2020. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. This is an Open Access
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Pathogenesis
 Are there specific changes in the vascular and dermal tissues
that are specific and relate to the development of new thera-
peutic approaches?
 What is the role of the dermal–epidermal disruption in the patho-
genesis and progression of podoconiosis?
Epidemiology and mapping
 What is the population at risk and number of cases in
the 14 countries with documented evidence of podoconio-
sis?
 What is the current status of the 15 historically endemic coun-
tries?
 Howcanpodoconiosis surveys be integratedwith other NTDs and
health surveys?
 How can podoconiosis be best included in routine national
reporting systems?
Disease burden
 What is the global burden of podoconiosis?
 What is the economic cost of control and elimination of podoco-
niosis?
Treatment
 What is the community-level impact of hygiene-basedmorbidity
management?
 Howmight adenolymphangitis be better characterized anddiag-
nosed?
 Does the addition of doxycycline to hygiene-basedmanagement
arrest progression of the disease or reduce the incidence of ade-
nolymphangitis?
 What other interventions applied to the management of lym-
phoedema in high-income counties could be added to hygiene-
based management?
 What is the optimal duration of supervised hygiene-based mor-
bidity management?
Prevention and control strategies
 Which behavioural interventions aremost effective in promoting
sustained changes in preventive behaviour?
 Under what circumstances should community-based
rather than facility-based morbidity management be pro-
vided?
 What is the optimal package of care for people with podoconio-
sis?
 What is the optimal surveillance, monitoring and evaluation
strategy for interventions against podoconiosis?
 Howmight podoconiosis control be integrated with that of other
NTDs and with other health programmes?
Disease burden, pathogenesis, epidemiology
and mapping
Podoconiosis is caused by exposure to mineral particle–induced
inflammation on a background of genetic susceptibility.1 Inter-
actions between genetic and environmental factors trigger an
inflammatory response that leads to lymphoedema and fibro-
sis.1 It is hypothesized that mineral particles that penetrate bare
skin are engulfed by macrophages in the lower limb lymphatics
and induce an inflammatory response in the lymphatic vessels.
This is followed by fibrosis and obstruction of the vessel lumen,
leading to oedema of the lower leg, which may progress to lym-
phoedema.9 Amuch better understanding of the pathogenesis of
podoconiosis, focussing on changes in the skin and the lymph sys-
tem, are critical in order to develop diagnostics and better treat-
ment. For example, are the pathological changes in the lymphatic
vessels and system similar to those proposed in lymphoedema
of parasitic origin (lymphatic filariasis [LF])? In the latter condi-
tion, it is thought that the parasite induces hyperproliferation of
the lymphatic vessels, leading to vascular incompetence. Knowl-
edge of temporal changes to the anatomy and drainage effi-
ciency of the lymph vessels should allow for improved therapeu-
tic measures and diagnostic interpretation of early changes. The
nature of functional changes in the dermal–epidermal tissues in
the affected region could also be informative.10,11 With the more
extensively studied lymphoedema in filariasis it is now thought
that the maintenance of upper dermis and epidermis is crucial to
healing and recovery.10,11 The skin is known to be a major source
of active protective and sometimes inflammatory molecules, for
example, in its role as a component of the body’s innate immu-
nity. Understanding changes in the skin as podoconiosis develops
and following treatment are fertile areas for investigation and
could in all likelihood contribute to developing and monitoring
new therapeutic approaches. Studies that will elucidate further
the genetic basis of susceptibility and the pathogenic pathways
the minerals trigger should be continued and extended.
Globally it is estimated that there are about 4 million people
with podoconiosis, mainly in tropical Africa, Central and South
America and Southeast Asia.12,13 Tropical African countries bear
the highest disease burden.14–16 A recent systematic review iden-
tified 32 countries where the disease has been reported either
currently or historically.13 Another study, which used a combi-
nation of evidence sources, concluded that there is evidence
of podoconiosis in 17 countries (12 in Africa, 3 in Latin Amer-
ica and 2 in Asia) and consensus on its presence in a further 6
countries (all in Africa) (Figure 1).17 So far only three countries
(Cameroon, Ethiopia and Rwanda) have conducted nationwide
mapping of podoconiosis as part of developing the global atlas
of the disease.12,16,18,19 A scalable mapping approach utilizing
mobile phone and geographic information system technologies
has been developed and applied in these three countries.16,18,20
In addition to community-based surveys, the mapping approach
uses remote sensing advances to produce datasets that define
areas at risk of podoconiosis using a combination of climate, envi-
ronmental and ecological parameters.21 The approach enables
clear definition of the geographical distribution of the disease and
estimation of the population at risk and the number of individuals
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Figure 1. Global distribution and prevalence of podoconiosis. This figure was adapted from Deribe et al.13 and is available for distribution under the
terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution and reproduction in any medium.
is critical that mapping is completed in the remaining countries
in which there is clear evidence of podoconiosis.
Estimating the global burden of podoconiosis is vital. Such
data provide policy makers, programme planners and clinical
practitioners clear burden estimates that help in priority setting
and decision making. Strong country-level data spur engage-
ment of endemic countries’ medical and public health communi-
ties and prompt national implementation. A study conducted in
Ethiopia estimated the disability-adjusted life years (DALYs) due
to podoconiosis sequelae (lymphoedema and acute attack) to
be 172 073, higher than the DALYs due to other NTDs, includ-
ing trachoma, onchocerciasis and leishmaniasis.22 Studies have
clearly shown an association between depression and podoco-
niosis, one documenting a prevalence of depression of 12.6%
among people with podoconiosis compared with 0.7% among
healthy neighbours.5 In the future, burden estimation should
establish podoconiosis-appropriate disability weights and include
anxiety and depression as a further sequela of podoconiosis
(Box 1).
Some of the environmental factors that facilitate formation
of the red clay soils containing the putative inorganic particles
that trigger the inflammatory response leading to podoconiosis
have been described.23 The exact causal agent in red clay soil
areas has not yet been identified. A range of studies has sug-
gested that mineral particles present in red clay soils play a role
in the pathogenesis of podoconiosis.24–28 Electron microscopy
microanalysis of lower limb lymphatic tissues of barefoot peo-
ple from Ethiopia indicated the presence of microparticles con-
taining the elements found in clays, with some difference in the
amount between affected and unaffected individuals.29 Studies
to better characterize the types of soils and soil particles in diverse
geographical areas are required.
In the early 1970s, Price9 reported familial aggregation of
podoconiosis in Ethiopia, Rwanda and Burundi. These observa-
tions and subsequent epidemiological studies in Ethiopia hinted
at a high heritability of podoconiosis.30–33 Price performed seg-
regation analysis, which suggested the possibility of a genetic
factorwith an autosomal recessivemode of inheritance.34 Subse-
quently it was hypothesized that individual differences in the tis-
sue handling of absorbedminerals play a role in the development
of full-blown podoconiosis.35 A pedigree study conducted in 2005
in southern Ethiopia illustrated that both genetic and environ-
mental factors contribute to the pathophysiology of podoconio-
sis.8 A genome-wide comparison of the frequency of genetic vari-
ants between podoconiosis cases and unaffected controls from
southern Ethiopia revealed that genetic variants in the human
leucocyte antigen locus (a genomic region on chromosome 6)
confer susceptibility to podoconiosis. The study suggested that
podoconiosis is a T cell–mediated inflammatory condition.7 Fur-
ther studies to replicate these findings in different populations are
required.
Diagnosis
Currently podoconiosis diagnosis is primarily clinical and based
on history, physical examination and certain disease-specific
tests to exclude common differential diagnoses.20 Current
ongoing studies include developing a clinical algorithm, testing
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system36,37 and using bioelectrical impedance analysis38 to
detect early, and therefore reversible, lymphoedema due to
podoconiosis. The clinical algorithm depends on history and
physical examination, suggesting that detailed phenotyping
might be an important preliminary step. Although it has high
sensitivity and specificity, validation in a range of epidemiolog-
ical and geographical settings will be required and should be
accompanied by the development of training materials. The use
of geographical characteristics such as altitudinal difference with
LF is important given the altitudinal limits of Anopheles vectors
of filariae (and malaria) transmission around 1700 m.20
Innovation in the diagnosis of podoconiosis is important
to accelerate the mapping, scale-up of interventions and ulti-
mately elimination of podoconiosis. Spectroscopy combinedwith
machine learning has been used to predict the risk of diseases,39
to accurately distinguish between vertebrate blood meals in
the guts of malaria mosquitoes40,41 and to identify sources of
dog diets.42 The method has also been applied for studying
the vibrational fingerprint of organic compounds through imag-
ing analysis. This approach could, in the future, be applied to
podoconiosis, possibly through scanning the skin and lymphatic
system changes or using non-invasive procedures such as hair
samples. The application of such technology could have impor-
tant implications for the diagnosis of podoconiosis in the short
term. Nonetheless, the long-term goal should be a point-of-care
diagnostic for podoconiosis.
A point-of-care diagnostic tool is critical for rapid scale-up
of mapping and interventions in endemic countries. Identify-
ing potential biomarkers is important to achieve this goal. We
hypothesize that as the pathogenesis of podoconiosis is likely
to involve activation of monocyte–macrophage cells lines (catal-
ysed by mineral elements), determining increases in circulating
biomarkers of macrophage activation will be important.43
The diagnosis of sequelae is also important. At present,
episodes of acute dermatolymphangioadenitis are diagnosed
clinically. Standardising clinical definitions and repositioning
other approaches such as thermography to detect secondary
inflammation will enable improved identification of these
episodes.
Prevention and control strategies
The key strategy for podoconiosis control is prevention of contact
with irritant soil through footwear use, foot hygiene and cover-
ing floors.44 Although important formative work has uncovered
many of the barriers to adoption of preventive behaviours,45,46
evidence around the effectiveness of behavioural interventions is
less conclusive.47 Evaluation of behavioural interventions, includ-
ing community conversations and patient-led groups, will be crit-
ical to the development of robust prevention strategies. Contin-
uing to engage social and behavioural scientists in developing
robust strategies is critical.
The basic package of care for patients includes treatment for
and management of episodes of lymphoedema morbidity, as
recommended by World Health Organization (WHO). This sig-
nificantly improves quality of life by reducing the frequency of
acute attacks and preventing disease progression.48,49 A recent
randomized controlled trial demonstrated that hygiene-based
management reduced the incidence of episodes of acute der-
matolymphangioadenitis by 20% at the 12-month follow-up.48
While the results of the trial are encouraging, the long-term
effects and degree of adherence should be studied, as should the
community-level impact of the intervention. Efforts to reduce the
water requirements of standardmorbidity management through
the addition of glycerine during foot soaking are promising and
should be included in future operational research where glycer-
ine is available.50 Morbidity management is one aspect of treat-
ment for people with podoconiosis. There is also a need to test
a comprehensive care package addressing the psychosocial and
mental health needs of affected individuals in addition to their
physical care.
Cross-sectional studies have suggested that doxycycline has
beneficial effects among people with LF.51,52 A small prospective
study in Ghana compared patients with LF treated with either
doxycycline, amoxicillin or placebo and followed the progress of
their lymphoedema over a 24-month period after treatment.53
The study demonstrated that doxycycline arrested progression of
the disease and reduced acute episodes. Currently a large-scale
study is under way in six countries to investigate the impact of
6 weeks of treatment with doxycycline added to standard limb
hygiene on early stage filarial lymphoedema and podoconiosis.54
Results will be available in 2021. The rich parallels between skin
changes in podoconiosis and LF suggest future opportunities for
research into therapeutics that span the interface between these
conditions.
Linking podoconiosis research to mainstream clinical derma-
tology research will be of significant benefit. Innovations being
developed for skin conditions with similar dermal–epidermal dis-
ruption and fibrotic manifestations may have important impacts
on restoring the cutaneous barrier in patients with podoconio-
sis. This goal has been greatly enhanced by two major issues:
first, the considerable amount of fieldwork carried out in the
past few years, and second, the new dermatology-focused ini-
tiatives of the WHO related to NTDs.55 The increased awareness
of podoconiosis and themove to integrate issues such as diagno-
sis and implementation of care for dermatosis seen in the tropi-
cal regions of the world describe a situation that is favourable to
increased research efforts in all areas of this condition. It is impor-
tant that dermatologists and researchers seize this opportunity
to discover more about podoconiosis and its treatment. One cur-
rent example of integrating podoconiosis with research into other
dermatological NTDs is the ongoing clinical trial to investigate
the impact of 6 weeks of treatment with doxycycline added to
standard limb hygiene on early stage lymphoedema in six sites
in Africa and the Indian subcontinent.54
Programme implementation
The scale of the burden of podoconiosis in endemic countries is
so significant that morbidity management must be approached
systematically14,15 and in an integrated manner. The WHO NTD
Roadmap 2021–2030 signals movement away from single dis-
ease silos towards integrated programmes.55 Currently morbidity
management services are mostly provided on a small scale by
non-governmental organizations in most endemic countries.
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overdue and will require certain key programmatic adaptations.
It is critical that ministries of health in endemic countries take
the lead in designing interventions and implementations. The
Ethiopian experience can be taken as an example.56 At the
national level, podoconiosis was included in the NTDs master
plan.57 In the national NTDs unit, a focal person responsible for
the implementation of podoconiosis was assigned and an inte-
grated morbidity management manual for LF and podoconiosis
was developed. Podoconiosis prevention and morbidity manage-
ment were included in the annual refresher training package for
healthcare providers. An indicator to track the number of people
treated for lymphoedema was included in the national Health
Management Information System.56 Podoconiosis interventions
were included in the national Essential Health Services Pack-
age.58 All these are important prerequisites for the integration of
morbidity management into the national health system.
In endemic countries, podoconiosis is oftenmisdiagnosed and
there are often misconceptions about the causes, prevention
and treatment of podoconiosis.59 Therefore formative research to
understand these misconceptions and service barriers is impor-
tant to develop tailored messages and behavioural change and
social mobilization strategies. Integration of clear, compelling
information on podoconiosis intomedical, nursing and paramed-
ical curricula will be vital in equipping the next generation of
healthcare professionals.
Well-designed implementation research is required to under-
stand how best to integrate podoconiosis interventions into the
health system. Implementation research assessing the integra-
tion and scale-up of a holistic package of care—including physical
health, mental health and psychosocial care—into routine health
services for patients with podoconiosis, LF and leprosy is ongo-
ing in northern Ethiopia. The study involves the development of
a comprehensive holistic care package, a pilot study conducted
in one subdistrict and scale-up of the care package and evalu-
ation in regard to coverage, implementation and economic out-
comes.60 Rehabilitation services to address the physical andmen-
tal health needs of people with podoconiosis are also important.
Designing minimummental health service packages that can be
integrated within the morbidity management package is also a
priority.
The development of a framework and tools for surveillance,
monitoring and evaluation with key programme-level indicators
is important. Implementation research on active surveillance
based on environmental, behavioural and climatic risk factors
and mandatory passive surveillance is also necessary. From the
patient side, behavioural change to encourage early presentation
for treatment screening will be important. Given the strong heri-
tability of susceptibility to podoconiosis, a family-based approach
to interventions targeting those with a family history may be
an important entry point. The use of school-based programmes
for health education and to initiate early shoe wearing must be
tested. Research linked to the implementation of programmes
and challenges that programmes face as they mature requires
social science involvement to improve coverage and adherence.
Global-level guidance by the WHO is required in terms of
what types of intervention and service-delivery modalities are
appropriate, based on endemicity level. In high-burden areas,
community-level interventions will be essential. Thus guidance
for developing community-level service provision is important.
In low-prevalence settings, intensified case management ser-
vices integrated within primary healthcare are sufficient. Sup-
plies required for morbidity management should be included in
the essential drug and medical supply lists of endemic coun-
tries to stimulate resource mobilization, procurement and distri-
bution. The global economic costs of intervention should also be
estimated to build a strong case for investment.
Conclusions
Much progress in podoconiosis research and intervention has
been made over the past 5 y, particularly through careful eval-
uation of the effectiveness of a morbidity management inter-
vention appropriate for low-resource settings. Preventive inter-
ventions addressing behavioural change and development of a
mapping strategy have also been important. This reviewhas iden-
tified research gaps that include estimating the global burden
of podoconiosis, developing point-of-care diagnostics, creating
innovative approaches to enhanced treatment, evaluating large-
scale community-level control strategies and the need for inte-
gration of podoconiosis into medical education. Finally, strong
advocacy is required to advance the control and elimination of
podoconiosis globally.
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